What we are studying
This study, which was mandated by the United States Food and Drug Administration (FDA), is being done to help answer an important safety question about long acting beta-agonists, a type of drug to treat asthma, specifically formoterol, a component of Symbicort.
People with asthma are at risk for uncommon but serious problems such as hospitalization, needing to have a tube put down their throat to help them breathe, or death due to asthma. The question is whether patients taking inhaled corticosteroids such as budesonide in combination with formoterol (Symbicort) have the same risk of having these serious problems as patients taking the inhaled corticosteroids (budesonide) alone.
You will be paid $495.00 to compensate you for your time and travel in this study if you complete all the scheduled study visits.